MetaCap

Tonix Pharmaceuticals (TNXP) vs Verrica Pharmaceuticals (VRCA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Verrica Pharmaceuticals (VRCA) has outperformed Tonix Pharmaceuticals (TNXP) over the past year, losing 34.9% versus a loss of 85.2%. Over five years, VRCA leads with a -97.4% price change compared with -100.0% for TNXP. Verrica Pharmaceuticals is the larger company by market cap ($47.1 million vs $46.2 million), about 1.0 times the size.

Verrica Pharmaceuticals converts more of its revenue into profit, with a net margin of -50.3% versus -946.2%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

TNXP-85.22%VRCA-34.92%
+126%+15%-95%
Nov 21, 20251 yearNov 20, 2026
TNXP-100.00%VRCA-97.60%
+12%-47%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

TNXP versus VRCA key metrics
MetricTNXPVRCA
Share price$2.38$2.74
Market cap$46.25M$47.07M
1-day change-6.67%-5.03%
YTD return-84.76%-67.03%
1-year return-85.22%-34.92%
5-year return-100.00%-97.38%
EPS (TTM)$-12.39$-2.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$13.11M$35.58M
Revenue growth (YoY)+29.85%+370.22%
Net income (latest FY)$-124.02M$-17.89M
Gross margin49.34%—
Operating margin-959.05%-34.25%
Net margin-946.22%-50.27%
52-week high$20.56$9.82
52-week low$2.30$2.73
Distance from 52-week high-88.42%-72.10%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1769.75%+404.74%
Average volume838.83K68.78K
Shares outstanding19.43M17.18M
Employees14276
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • VRCA has outperformed TNXP by 50.3 percentage points over the past year.
  • Verrica Pharmaceuticals is more profitable, keeping -50.3 cents of every revenue dollar as net income versus -946.2 cents for Tonix Pharmaceuticals.
  • Verrica Pharmaceuticals grew revenue faster in its latest fiscal year (+370.22% vs +29.85%).

About Tonix Pharmaceuticals

TNXP stock →

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.

Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees

About Verrica Pharmaceuticals

VRCA stock →

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

TNXP vs VRCA FAQ

Which is bigger, Tonix Pharmaceuticals or Verrica Pharmaceuticals?

Verrica Pharmaceuticals (VRCA) is larger, with a market capitalization of $47.07M compared with $46.25M for Tonix Pharmaceuticals (TNXP).

Which stock has performed better over the past year, TNXP or VRCA?

VRCA returned -34.92% over the past 12 months, compared with -85.22% for TNXP (price return, excluding dividends). Past performance does not predict future results.

Are Tonix Pharmaceuticals and Verrica Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons